Could a targeted drug make stem cell transplants more effective for tough blood cancers?
NCT ID NCT03613532
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing whether adding the drug venetoclax to standard chemotherapy before and after a bone marrow transplant can help prevent cancer from coming back in people with high-risk acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or related blood cancers. About 102 participants will receive venetoclax alongside standard conditioning drugs before transplant, and then as maintenance therapy afterward. The main goal is to find safe doses and schedules, while also tracking survival and relapse rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Venetoclax (a targeted drug) combined with chemotherapy drugs (fludarabine, busulfan, azacitidine, decitabine/cedazuridine)
What this could lead to
If successful, this could lead to a safer and more effective way to prevent cancer relapse after a bone marrow transplant for people with high-risk blood cancers.
What could go wrong
This is an early-phase (Phase 1) trial focused on safety and dosing, so it is too soon to know if it works. Adding venetoclax may increase side effects like infections or organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States